The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Collaboration revenue | 6,646 |
| Total operating expenses | 154,350 |
| Loss from operations | -147,704 |
| Interest income | 11,052 |
| Change in fair value of stock price appreciation milestones | -244 |
| Other income | 93 |
| Total other income | 11,389 |
| Net loss | -136,315 |
| Depreciation and amortization | 12,901 |
| Stock-based compensation | 24,924 |
| Accretion and amortization of premiums and discounts on investments, net | 3,606 |
| Deferred revenue | -12 |
| Changes in fair value of stock price appreciation milestones | -244 |
| Impairment of long-lived assets | 0 |
| Loss on disposal of property and equipment | -9 |
| Accounts receivable | -2,624 |
| Prepaid expenses and other assets | -5,179 |
| Accounts payable and accrued expenses | -9,027 |
| Right-of-use assets and lease liabilities, net | -2,517 |
| Net cash used in operating activities | -106,084 |
| Proceeds from sale of property and equipment | 362 |
| Purchases of property and equipment | 5,953 |
| Purchases of investments | 195,143 |
| Maturities of investments | 311,900 |
| Net cash provided by investing activities | 111,166 |
| Issuance of common stock from equity incentive plans, net of issuance costs | 0 |
| Proceeds from public offering of common stock, net of issuance costs | 0 |
| Proceeds from issuance of pre-funded warrants, net of issuance costs | 0 |
| Proceeds from ft819 cirm award | 1,490 |
| Proceeds from ft836 cirm award | -4,000 |
| Net cash provided by financing activities | 5,490 |
| Net change in cash, cash equivalents and restricted cash | 10,572 |
| Cash, cash equivalents and restricted cash at beginning of the year | 46,283 |
| Cash, cash equivalents and restricted cash at end of the year | 56,855 |
FATE THERAPEUTICS INC (FATE)
FATE THERAPEUTICS INC (FATE)